Inclusion Criteria:

• Subject is greater than 18 years of age.
• Subject has a calculated creatinine clearance of 20-50 mL/min (within 10 days prior to enrollment), per the Cockcroft-Gault formula.
• Subject is eligible for coronary angiography (with or without ventriculogram) and/or percutaneous coronary intervention in which it is anticipated that > 50cc of radiographic contrast will be administered.
• Subject agrees to comply with the study procedures, including repeat phlebotomy and clinical follow-up.
• Subject or subject's legal representative is willing to provide written, informed consent to participate in this clinical study.

Exclusion Criteria:

• Subject is currently undergoing renal dialysis.
• Subject is in acute renal failure or has unstable renal function as evidenced by clinical findings or a change in serum creatinine of >= 0.5 mg/dL or >= 25% within 10 days prior to enrollment.
• Subject is undergoing planned renal artery catheterization, or infusion of medications or therapeutic agents directly into the renal arteries.
• Subject is hypotensive [systolic blood pressure (SBP) <100 mmHg].
• Subject has had an acute ST-segment elevation myocardial infarction (MI) within 72 hours prior to enrollment, or is currently having an acute ST-segment elevation MI.
• Subject has decompensated heart failure as defined by the requirement for IV diuretic, inotropic or vasopressor support within the last 7 days.
• Subject requires respiratory support.
• Subject has a known allergy to iodine-based contrast agents that cannot be pre-medicated.
• Subject has received a radiographic contrast agent within 10 days prior to enrollment or a second imaging study is planned within the next 10 days.
• Subject is receiving mannitol or IV diuretics.
• Subject has known renal artery stenosis.
• Subject is currently on a course of chemotherapy.
• Subject has any serious medical condition, which in the opinion of the investigator is likely to interfere with study procedures.
• A plan exists for the addition, discontinuation or dose-adjustment of ACE inhibitors, angiotensin II blockers, trimethoprim, cimetidine, metoclopramide, bromocriptine, levadopa, non-steroidal anti inflammatory drugs (NSAIDs), COX-2 inhibitors, or catechol-O-methyltransferase (COMT) inhibitors (e.g., encapone or tolcapone) at any time during the study.
• Subject has a known hypersensitivity to hypothermia, including a history of Raynaud's Disease.
• Subject has a known hypersensitivity to heparin which cannot be adequately pre-medicated
• Subject has a known history of bleeding diathesis, coagulopathy, sickle cell disease, cryoglobulinemia, or will refuse blood transfusions.
• Subject has a height of < 1.5 m (4 feet 11 inches).
• Subject has an Inferior Vena Cava filter in place.
• Subject is pregnant. (Female subjects of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to enrollment)
• Subject has a known hypersensitivity to buspirone hydrochloride or meperidine and/or has been treated with a monoamine oxidase inhibitor in the past 14 days.
• Subject has a known history of severe hepatic impairment, untreated hypothyroidism, Addison's Disease, or Benign Prostatic Hypertrophy or urethral stricture that in the physician's opinion would be incompatible with meperidine administration.
• Subject has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely to comply with study follow-up requirements.
• Subject is currently enrolled in this trial or in another investigational drug or device trial. Note: For the purpose of this protocol, subjects involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.